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Abstract 
Postoperative residual muscle paralysis can lead to very serious complications, such as 
hypoxia, airway obstruction, and generalized muscle weakness after surgical procedures.  
Traditional anesthesia practice has utilized a class of medications called cholinesterase 
inhibitors to mitigate these complications.  Cholinesterase inhibiting agents have the 
potential to create adverse effects of their own, such as bradycardia, due to the drug 
class’s indirect mechanism of action.  An ideal reversal agent would reverse quickly, and 
reliably, with minimal adverse effects.  Recently, sugammadex, a selective relaxant-
binding agent, has been introduced as an alternative reversal agent.  The purpose of this 
systemic review was to compare the administration of sugammadex versus neostigmine 
and time to re-establish normal muscular function, as evidenced by a train-of-four (TOF) 
ratio of 0.9.  Databases were searched for pertinent randomized control trials and 
literature regarding the topic of this review.  Inclusion and exclusion criteria were utilized 
to finalize the five studies that were included in this systematic review.  The PRISMA 
checklist and CASP tool was utilized to extract and critically appraise each study.  
Additionally, a cross study analysis was performed.  Overall, sugammadex was found to 
be a faster and more reliable reversal agent, with mild-to-moderate adverse effects 
reported, when compared to the anticholinesterase, neostigmine.  Consistently and 
reliably reversing neuromuscular blocking agents and educating other health care 
professionals about the negative consequences of postoperative residual muscle paralysis, 
are initiatives that the advance practice nurse, particularly the CRNA, can lead.  
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A Systematic Review Comparing Neostigmine Versus Sugammadex For Reversal of 
Rocuronium-Induced Neuromuscular Blockade  
Background/Statement of the Problem 
Muscle relaxation induced by neuromuscular blocking agents (NMBAs) has been 
commonly used in anesthesia practice to enable paralysis.  NMBAs facilitate tracheal 
intubation by paralyzing the vocal cords, allowing an endotracheal tube to pass without 
causing laryngeal trauma.  Additionally, the paralysis induced by NMBAs during surgery 
assists to optimize surgical conditions by relaxing the skeletal musculature, inhibiting 
reflexive movement to noxious surgical stimuli, and inhibiting spontaneous ventilation 
(Kirkland, 2013). 
 In the United States, routine practice of reversing non-depolarizing NMBAs 
varies amongst anesthesia providers.  The potential for residual paralysis caused by an 
incomplete non-depolarizing NMBA reversal could negatively impact patients in the 
post-operative period.  Post-operative residual paralysis (PORP), defined as muscle 
weakness due to incomplete or absent antagonism of non-depolarizing neuromuscular 
blockers, has been shown to increase morbidity and mortality (Mathias & Bernardis, 
2012).  Mathias and Bernardis (2012) identified complications of residual paralysis to 
include: increased risk of regurgitation due to weakness in the hypoglossal and 
esophageal sphincter muscles, hypoxia, airway obstruction, generalized muscle 
weakness, and difficulty speaking or drinking.  The primary prevention strategy for 
PORP and subsequent complications has been pharmacologic reversal, which ensures 
safety and termination of the NMBA effect (Kirkland, 2013).  
Anesthesia practice has traditionally reversed neuromuscular blockade with a 
cholinesterase inhibitor, neostigmine, administered concurrently with an anticholinergic 
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agent, such as atropine or glycopyrrolate.  Cholinesterase inhibitors work indirectly, 
increasing the amount of acetylcholine available within the neuromuscular junction 
(NMJ), to compete for binding sites on the muscle’s nicotinic acetylcholine receptor 
(Welliver, 2013).  Limitations and adverse effects exist with the use of cholinesterase 
inhibitors due to the drug’s indirect mechanism of action.  Adverse effects of 
cholinesterase inhibitors result from excess acetylcholine and include: bradycardia, 
increased gastric motility, airway secretions, bronchoconstriction, and arrhythmias 
(Nagelhout, 2013).  An anticholinergic agent administered concurrently with 
cholinesterase inhibitors has traditionally been used to blunt the degree of adverse effects.  
One of the main limitations of using cholinesterase inhibitors has been the inability to 
produce a consistent and reliable train-of-four (TOF) ratio of 0.9 within 30 minutes 
(Nagelhout, 2013).  TOF, a method of nerve stimulation, utilizes a peripheral nerve 
stimulator (PNS) to deliver four electrical impulses every 0.5 seconds at a frequency of 
two hertz for a total of two seconds, to determine depth of neuromuscular blockade 
(Nagelhout & Plaus, 2014).  Each of the four impulses causes a muscle twitch, referred to 
as T1 through T4.  The TOF ratio uses an accelerometer to quantitatively compare the last 
twitch, T4, to the first twitch, T1, to yield a numeric ratio.   
 The varying degree of effectiveness and unpleasant side effects of cholinesterase 
inhibitors led to the investigation of alternative reversal agents.  Ideally, a reversal agent 
would provide a rapid onset, produce minimal adverse effects, and re-establish muscle 
function reliably and consistently, regardless of neuromuscular blockade depth 
(Nagelhout, 2013).  
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 Sugammadex, a reversal agent specific for the aminosteroid class of non-
depolarizing NMBAs, was initially studied with the intent that the compound would 
increase the solubility of the NMBA, rocuronium, in specific media.  However, while 
under investigation, sugammadex was observed to permanently bind with the rocuronium 
molecule (Welliver, 2013).  The irreversible bond of sugammadex and rocuronium 
created a stable and inactive complex that was eliminated by the kidneys.  Clinical trials 
have shown sugammadex to be exponentially faster in reversing rocuronium-induced 
block, when compared to neostigmine, due to the direct mechanism of action (Welliver, 
2013). 
 Therefore, the purpose of this paper was to complete a systematic review to 
compare the administration of sugammadex versus neostigmine and time to re-establish 
normal muscular function, as evidenced by a TOF ratio of 0.9.  
 Next, a review of the literature will be presented.   
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Literature Review 
The primary databases searched were CINHAL Plus with full text, PubMed, and 
the Cochrane Library.  The key words used in the literature search were neuromuscular 
blockade, sugammadex, neostigmine, and rocuronium.  The key words were searched 
separately and combined to generate results over a period of ten years, from 2008- 2018.  
Neuromuscular Junction Anatomy & Physiology 
 The nerves of the peripheral nervous system regulate skeletal muscle contraction 
and relaxation.  The anatomical region where the nerve and skeletal muscle synapse is 
referred to as the neuromuscular junction (NMJ).  The NMJ is comprised of three major 
structural components: the pre-synaptic nerve, synaptic cleft, and the postsynaptic muscle 
membrane.  Acetylcholine (ACh) is the chemical transmitter that is responsible for 
communication between the pre-synaptic nerve and the postsynaptic muscle membrane.  
An action potential causes depolarization of the pre-synaptic nerve, releasing ACh 
molecules into the synaptic cleft.  ACh diffuses across the cleft to the postsynaptic 
muscle membrane, specifically the motor end plate, where it binds to the muscle’s 
nicotinic acetylcholine receptor (nAChR) (Plummer-Roberts, Trost, Collins, & Hewer, 
2016).   
 The muscle’s nAChR is a complex composed of five subunits: two alpha (a) 
subunits, and one of each: beta (b), delta (d), and epsilon (e) subunits.  These subunits are 
organized cylindrically to form a transmembrane channel.  When ACh occupies each of 
the a-subunits, the nAChR undergoes a conformational change opening the channel, 
allowing sodium and calcium influx, and potassium efflux in the skeletal muscle  
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(Plummer-Roberts et al., 2016).  Sodium entry into the skeletal muscle activates the 
muscle’s sarcoplasmic reticulum to release calcium and induce skeletal muscle 
contraction.  
 Acetylcholinesterase is an enzyme that is present at the motor end plate of the 
skeletal muscle membrane.  Once ACh is inactivated by acetylcholinesterase at the 
nAChR, skeletal muscle relaxation ensues.  This enzyme hydrolyzes ACh into its inactive 
constituents: acetate and choline.  Acetate and choline constituents are recycled to 
synthesize subsequent ACh molecules to allow for ensuing skeletal muscle contraction 
(Plummer-Roberts et al., 2016).   
Neuromuscular Blockade 
 Neuromuscular blockade, also referred to as muscle relaxation, occurs when 
transmission of the nerve impulse at the NMJ is blocked, inhibiting skeletal muscle 
contraction.  NMBAs exert their effect by altering the ability of the chemical transmitter 
ACh to bind to the muscle membrane’s nAChR.  There are two classes of NMBAs that 
can be used to accomplish muscle relaxation: depolarizing agents and non-depolarizing 
agents (Kirkland, 2013). 
Use of an NMBA may be required to facilitate tracheal intubation or inhibit 
spontaneous, reflexive movements to safely complete an operation.  The depth and length 
of muscle relaxation required is dependent on the surgical procedure performed.  For 
example, if skeletal muscle tone is to affect operating conditions and surgical outcomes, 
then muscle relaxation with the use of NMBAs would be beneficial (Kirkland, 2013).  
One commonly cited surgical procedure requiring muscle relaxation is laparoscopic 
surgery in an area near the patient’s diaphragm.  Cited benefits of paralysis for this type 
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of procedure include: immobility, enhanced vision, and improved access to the surgical 
field (Kirkland, 2013).  
 Non-depolarizing agents.  Non-depolarizing NMBA’s work by competitively 
binding one of the two a-subunits on the muscle’s nAChR, a mechanism referred to as 
“antagonizing”.  Blockade of one a-subunit on the nAChR, prevents the neurotransmitter 
ACh from binding the required two a-subunits to induce skeletal muscle contraction.  
This mechanism prevents depolarization at the skeletal muscle’s motor end plate, 
resulting in muscle paralysis (Plummer-Roberts et al., 2016).   
 Non-depolarizing agents are further classified into two categories: 
benzylisoquinoline and aminosteroid compounds.  The major difference between these 
drug categories is their pharmacokinetic profile.  Benzylisoquinoline blocking agents are 
eliminated by Hoffmann elimination, which relies on body temperature and pH to 
metabolize and eliminate the agents.  Aminosteroid blocking agents rely on hepatic and 
renal systems for metabolism and elimination.  Benzylisoquinoline blocking agents may 
be preferred in patients with liver or renal dysfunction, while aminosteroid blocking 
agents may be preferential in asthmatic patients due to the lack of histamine release.  
Commonly used agents in the aminosteroid class of NMBA’s include: pancuronium, 
rocuronium, and vecuronium (Papathanas & Killian, 2017).   
Residual Neuromuscular Blockade 
 The presence of skeletal muscle weakness after administration of a neuromuscular 
blocking agent is referred to as residual neuromuscular blockade (RNMB).  Wiatrowski, 
Martini, Flanagan, Freeman, and Sloan (2018) identified that RNMB occurs 
postoperatively in 20-60% of patients who receive non-depolarizing NMBAs.  The 
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sequelae that result from RNMB include airway obstruction, impaired oxygenation and 
ventilation, hypoxemia resulting in the need for re-intubation, as well as the risk for 
aspiration due to impaired pharyngeal reflexes (Wiatroswki et al., 2018).  These 
complications are serious, potentially life-threatening, and increase patient perioperative 
morbidity and mortality.  
Measures of monitoring neuromuscular blockade  
Administration of NMBAs requires vigilant assessment and observation by the 
anesthesia provider.  The practice standard set forth by the American Association of 
Nurse Anesthetists (AANA) requires monitoring of neuromuscular response to NMBAs, 
assessment of the depth of blockade and assessment of skeletal muscle recovery (AANA, 
2013).  An excessive dose of a NMBA may cause residual skeletal muscle paralysis post-
procedure, while an inadequate dose may result in unanticipated movement during 
critical portions of a surgical procedure (Nagelhout & Plaus, 2014).   
Experts endorse routine monitoring of neuromuscular blockade as a cornerstone 
of patient safety.  Monitoring neuromuscular blockade intraoperatively helps guide the 
anesthesia provider in determining the depth of muscle relaxation, while avoiding over-
paralysis and resulting post-operative residual paralysis (Nagelhout & Plaus, 2014).  
Anesthesia providers use a combination of clinical, qualitative, and quantitative measures 
to determine recovery from neuromuscular blockade.   
Qualitative measures. Qualitative monitoring is a form of subjective monitoring, 
which allows the anesthesia provider to assess the degree of blockade by a visual and/or 
tactile response to a stimulus.  Qualitative measures are commonly assessed by direct 
clinical tests or use of an electrical stimulus from a peripheral nerve stimulator (PNS) 
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(Mathias & Bernardis, 2012).  A peripheral nerve stimulator device can deliver various 
patterns of electrical impulses to a patient’s nerve through skin electrodes to evoke a 
predictable muscle contraction (Nagelhout & Plaus, 2014).  Common neuromuscular 
monitoring tests that are used to produce a predictable, visible pattern of muscle 
contraction include: single twitch, train-of-four, double-burst simulation, tetanus, and 
post-tetanic count (Appendix A). 
Train-of-four (TOF) monitoring. TOF monitoring exerts a series of four separate 
electrical impulses 0.5 seconds apart at a frequency of two hertz (Hz) for two seconds.  
This stimulus produces four observable muscle twitches, which are referred to as T1 
through T4, respectively (Nagelhout & Plaus, 2014).  Administration of a non-
depolarizing NMBA will result in progressive diminution of the twitch response to the 
electrical stimulus, a concept known as fade.  The fourth twitch (T4) will disappear first, 
as the neuromuscular block deepens there will be disappearance of the preceding 
twitches; T3, T2, and T1, respectively.  Twitches cannot be elicited when 100% paralysis 
is achieved (Nagelhout & Plaus, 2014).   
Of importance to the anesthesia provider is the comparison of the last twitch (T4) 
to the first twitch (T1).  Subjectively comparing T4 and T1 allows a determination of a 
train-of-four ratio (TOFR), which assists the provider in determining the level of 
neuromuscular blockade present.  A TOFR of 0.9 or greater is the accepted standard to 
determine adequate reversal from neuromuscular blockade, indicating that the fourth 
twitch (T4) response is 90% of the first twitch (T1).  Qualitatively measuring TOF may 
result in inter-rater variance and a reliable TOFR of 0.9 may not always be achieved 
(Wiatrowski et al., 2018). 
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Clinical Tests.  Clinical tests are subjective measurements of patient strength to 
determine whether RNMB is evident.  For example, the 5-second head lift test instructs 
the patient to lift their head from a pillow for a consecutive five seconds.  Recent data 
supports a patient can adequately complete this task despite a TOFR of 0.45-0.75 
(Wiatrowksi et al., 2018).  Another traditionally used clinical test is forced vital capacity 
(FVC), which is the maximum amount of air a person can exhale after a maximum 
inhalation.  A person with a TOFR of 0.5 can adequately complete a forced vital capacity 
breath (Wiatrowski et al., 2018).  The use of clinical tests to determine presence of 
neuromuscular blockade is not adequate to reliably ascertain a TORF of 0.9 (Wiatrowski 
et al. 2018).   
Quantitative measures. Quantitative monitoring allows an objective assessment 
to be made by the anesthesia provider.  Quantitative monitoring utilizes the same patterns 
of stimulation from a PNS and furthermore, couples the stimulus to a displacement 
transducer.  The displacement transducer acts as a movement measuring device and 
computes a numerical value.  Quantitative monitoring can be accomplished by using 
acceleromyography (AMG), electromyography (EMG), mechanomyography (MMG), 
and kinemyography (KMG) (Nagelhout & Plaus, 2014).  Mechanomyography measures 
the force of isometric contraction of a muscle after nerve stimulation.  Data analyzed 
from MMG devices assisted in the development of the gold standard TOFR of 0.9 to 
indicate adequate return of neuromuscular function; however, due to the cumbersome set-
up of MMG devices their use outside of research is minimal (Wiatrowski et al., 2018).   
In clinical practice, AMG devices are commonly used.  AMG measures isotonic 
contraction of muscle tissue in response to nerve stimulation, specifically a TOF 
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stimulation pattern at the level of the ulnar nerve (Wiatrowski et al., 2018).  The ulnar 
nerve innervates the adductor pollicis muscle of the thumb, and when stimulated causes 
the thumb to adduct.  This site is best for measuring recovery from neuromuscular 
blockade due to the pharmacodynamics of NMBAs and easy accessibility to providers.  
Coupling this stimulation to a displacement transducer allows an output to be computed 
to reflect an objective measure of the TOFR, and ascertainment of a TOFR of 0.9. 
Reversal Agents  
The risk of residual neuromuscular blockade and resulting skeletal muscle 
weakness drives the practice for administering reversal agents.  The ideal reversal agent 
would provide rapid, complete, and reliable reversal with minimal side effects (Welliver, 
2013).  Traditionally, a class of medications called anticholinesterases have been used to 
reverse neuromuscular blockade.  Anticholinesterase agents require a small degree of 
spontaneous skeletal muscle recovery to be efficacious in antagonizing muscle paralysis.  
Although commonly used in practice, anticholinesterase agents are not without side 
effects.  Co-administration of anticholinergics are used to reverse these untoward effects 
of anticholinesterases (Nagelhout, 2013). 
Research over the last decade has introduced a new class of medications, selective 
relaxant-binding agents (SRBAs), for reversal of neuromuscular blockade.  Sugammadex, 
a SRBA, has shown to be efficacious in reversing neuromuscular blockade regardless of 
depth of paralysis with minimal adverse effects.  Clinical trials have suggested that time 
to a TORF of 0.9 is decreased by using sugammadex as a reversal agent (Welliver, 2013).  
 Anticholinesterases.  Anticholinesterases are a class of medications that work to 
increase the amount of ACh available at the NMJ through blockade of the enzyme 
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acetylcholinesterase.  Allowing ACh to accumulate increases the probability that it will 
preferentially bind to the a-subunits on the nAChR, initiating skeletal muscle recovery 
(Plummer-Roberts et al., 2016).  The mechanism in which anticholinesterases exert their 
effect is primarily through antagonism of residual non-depolarizing NMBA molecules.  
Neostigmine is a commonly used anticholinesterase agent for reversal of neuromuscular 
block.  
Despite neostigmine’s mechanism of action, if the NMJ is highly concentrated by 
the NMBA, increasing ACh molecules may be inadequate to antagonize the NMBA 
(Jones, Caldwell, Brull, & Soto, 2008).  Anticholinesterase agents are efficacious only 
when a small degree of endogenous skeletal muscle recovery is present, therefore prudent 
TOF monitoring by the anesthetist is warranted to assess for twitch responses.  If 100% 
blockade is present at the NMJ, neostigmine is an ineffective antagonist; and may 
subsequently result in paradoxical muscle weakness if additional doses are administered 
when 100% of acetylcholinesterase is inhibited (Plummer-Roberts et al., 2016).  
 ACh is the primary chemical messenger in the parasympathetic nervous system.  
In addition to activating the nAChR in the NMJ, ACh can stimulate muscarinic receptors 
throughout the body.  Activating muscarinic receptors induces effects such as: 
bradycardia, bronchoconstriction, increased airway secretions, and increased gastric 
motility (Nagelhout, 2013).  To prevent the previously stated effects, an anticholinergic 
medication is administered concurrently to block activation of muscarinic receptors.  
Anticholinergic medications are not without side effects, which may include: blurred 
vision, dry mouth, urinary retention, and tachycardia (Nagelhout, 2013).  A commonly 
administered anticholinergic agent is glycopyrrolate.   
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 Pairing of neostigmine and glycopyrrolate is used in clinical anesthesia to reverse 
neuromuscular blockade.  The pairing of neostigmine and glycopyrrolate is preferential 
as the two agents have a similar onset and duration of action.  One of the main limitations 
of this traditional method of reversal is that the time to reliably produce a TOFR of 0.9 
within 30 minutes varies (Welliver, 2013).   
 Selective relaxant-binding agents.  Sugammadex is the only available selective 
relaxant-binding agent.  The structure of sugammadex is a modified g-cyclodextrin, 
resembling the shape of a hollowed cone.  The exterior of the cone is hydrophilic, and the 
interior is hydrophobic.  Hydrophobic interactions within the cone allow the steroidal 
NMBAs (rocuronium, vecuronium, and pancuronium) to be encapsulated by 
sugammadex in a 1:1 ratio.  The rocuronium-sugammadex complex has the highest 
association rate and does not easily dissociate; for every 30 million complexes formed, 
only one complex dissociates (Naguib, 2015).  By encapsulating the steroidal NMBAs, 
sugammadex leaves them unable to antagonize the nAChR (Plummer-Roberts et al., 
2016).   
 The mechanism sugammadex uses to encapsulate the rocuronium molecule is 
independent of enzyme systems and receptors in the body; therefore, sugammadex does 
not require co-administration of other pharmacologic agents (Naguib, 2015).  Due to the 
high affinity of sugammadex and rocuronium, clinical studies have shown that reversal of 
profound rocuronium-induced neuromuscular blockade is possible despite the lack of 
endogenous muscle recovery (Naguib, 2015).  The advantages of sugammadex include: 
reversal of any level of blockade within 3 minutes of administration when dosed 
appropriately, and lack of muscarinic side effects (Plummer-Roberts et al., 2016).   
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Studies Evaluating Blockade Reversal 
Acceleromyography using a train-of-four (TOF) mode of stimulation is a 
consistent method of measurement of neuromuscular blockade across randomized control 
trials. TOF stimulation generates four electrical impulses over 2 seconds, which evokes 
muscle twitching.  The mechanism of acceleromyography converts the measured 
accelerations into electrical signals (Kirkland, 2013).  The number, height, and 
acceleration of the four muscle twitches is recorded.  Prior to administering any NMBA, 
the four twitches should be of equal height, yielding a TOFR of 1.0.  Non-depolarizing 
NMBAs cause twitch height to fade as block depth increases, which decreases the TOFR 
(Kirkland, 2013).  A TOFR of 0.9 is considered the gold standard of adequate reversal of 
neuromuscular block.   
General surgical procedures.  Jones et al. (2008) conducted a phase III, 
multicenter, randomized control trial in the United States, comparing the use of 
sugammadex versus neostigmine for reversal of profound rocuronium-induced 
neuromuscular blockade.  This study included a sample size of 74 participants, American 
Society of Anesthesiologists (ASA) class I-IV, at least 18 years of age, undergoing an 
elective surgical procedure under general anesthesia in the supine position.  Participants 
were randomized to receive either 4.0mg/kg sugammadex (n=37), or 0.7mg/kg 
neostigmine plus 0.014mg/kg glycopyrrolate (n=37).  
After induction of general anesthesia, baseline neuromuscular function was 
established using acceleromyography.  Subsequently, participants received 0.6mg/kg of 
rocuronium for tracheal intubation and maintenance doses of 0.15mg/kg rocuronium as 
required by the surgical procedure.  When surgical conditions permitted, participants 
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were allowed to spontaneously recover until 1-2 post-tetanic counts (PTCs) were present, 
indicating presence of profound neuromuscular blockade (Reference Appendix A).  At 1-
2 PTCs a single dose of 4.0mg/kg sugammadex or 0.7mg/kg neostigmine plus 
0.014mg/kg glycopyrrolate was administered.  Neuromuscular monitoring via 
acceleromyography was maintained on each participant throughout the trial until a TOFR 
of 0.9 was re-established (Jones et al., 2008).   
Participants were assessed every 15 minutes after tracheal extubation until 
discharge from the post-anesthesia care unit (PACU).  A blinded assessor conducted 
assessments including: level of consciousness, a 5 second head-lift, and general muscle 
weakness via a rating scale of 1[extreme impairment] to 9 [no impairment], while 
monitoring for potential clinical signs of residual neuromuscular blockade (Jones et al., 
2008).  Participants who received sugammadex recovered to a TOFR of 0.9 within a 
geometric mean time of 2.9 minutes versus 50.4 minutes in participants who received 
neostigmine plus glycopyrrolate (P< 0.0001).  Jones et al. (2008) concluded that 
profound rocuronium-induced neuromuscular blockade could be more reliably and 
rapidly reversed by sugammadex than neostigmine.   
Blobner et al. (2010) conducted a quantitative, experimental, randomized control 
trial in Europe, comparing the efficacy of sugammadex and neostigmine for reversal of 
rocuronium-induced neuromuscular blockade.  A sample size of 98 participants, at least 
18 years of age, undergoing an elective surgical procedure were categorized into the ASA 
class I-III.  Participants were randomized into either the interventional group, which 
received sugammadex (n=49), or control group, which received neostigmine (n=49).  
When the participants did not require neuromuscular blocking agents any longer, they 
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were allowed to spontaneously recover until the appearance of a second twitch (T2) on 
TOF stimulation.  At T2 the dose of assigned medications was delivered: 2.0mg/kg of 
sugammadex or 50mcg/kg of neostigmine (with 10mcg/kg of glycopyrrolate).  In all 
participants, neuromuscular monitoring continued until recovery of the TOFR returned to 
0.9.  Upon arrival to the PACU, assessments were conducted of general muscle 
weakness, level of consciousness, and a 5 second head-lift test.  Within five minutes of 
administration of the reversal agent, 98% of sugammadex patients had recovered to a 
TOFR of 0.9, compared with 11% of neostigmine patients (P <0.0001).  In the 
neostigmine group, 101 minutes elapsed, before 98% of participants recovered to a TOFR 
of 0.9.  In this experimental study, drug related adverse effects were considered mild to 
moderate, and there were no participants eliminated from the trial due to an adverse 
event.    
Bariatric surgical procedures.  Gaszynski, Szewczyk, and Gaszynski (2011) 
conducted a quantitative, prospective, experimental, randomized study comparing 
sugammadex and neostigmine for reversal of rocuronium-induced muscle relaxation in 
morbidly obese patients undergoing elective bariatric surgery.  Pharmacologic alterations, 
specifically, delayed drug onset and peak of action, in most anesthetic drugs are observed 
in morbidly obese patients’ due to a greater volume of distribution.  The intent was to 
decrease time to recovery of neuromuscular function, measured by a TOF ratio of 0.9, 
and prevent PORP complications. Gaszynski et al. (2011) calculated the dose of the 
reversal agent in their study by using patient’s corrected body weight (CBW), instead of 
patient’s ideal body weight.  This calculation increased the amount of each reversal agent 
each patient received.  Seventy patients were randomized into either a sugammadex 
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intervention group (n=35) or neostigmine control group (n=35).  The sugammadex group 
received 2mg/kg of CBW, and the neostigmine group received 0.05mg/kg of CBW with 
concurrent administration of atropine 0.02mg/kg of CBW. 
 At the end of surgery, when accelerometry TOF stimulation exhibited two 
twitches, study drugs were administered, and time was recorded.  The mean time to 
neuromuscular recovery, as evidenced by a TOFR 0.9, was two minutes in the 
sugammadex group and nine minutes in the neostigmine group.  Ultimately, mean time to 
TOFR 0.9 was 3.5 times shorter in the sugammadex than the neostigmine group 
(Gaszynski et al., 2011).  Statistical t-tests identified a p value of <0.05 as a significant 
finding.  There was a statistically significant difference in recovery to reestablish 
muscular function between sugammadex and neostigmine (p<0.05).  One episode of 
profound bradycardia was assessed in the neostigmine group after administration of the 
study drug (Gaszynski et al., 2011).  This adverse effect could have been due to using 
CBW instead of ideal body weight.   
 Alsaeed,et al. (2017) conducted a prospective randomized trial in Saudi Arabia 
comparing reversal of rocuronium blockade with sugammadex 2mg/kg of CBW versus 
two different dosages of neostigmine, 2.5mg and 5mg.  A sample size of 110 participants 
with a body mass index (BMI) >40, undergoing elective gastric sleeve (bariatric) surgery 
with general anesthesia were enrolled in this study.  All participants were monitored 
intraoperatively with neuromuscular transmission monitoring (NMT).  Randomization of 
participants into one of three groups was accomplished by use of sealed envelopes and a 
randomization table.  At the completion of surgery PTCs and TOF count were recorded.  
The TOF count recorded immediately prior to the injection of the reversal agent in 
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Groups A, B, and C, was 2 twitches, 1 twitch, and 1 twitch, respectively.  Subsequently, 
Group A (n=38) received sugammadex 2mg/kg of CBW, Group B (n=41) received 
neostigmine 2.5mg, Group C (n=31) received neostigmine 5mg.   
 A timer was used to record the seconds until a TOFR of 0.9 was achieved.  Group 
A achieved a TOFR of 0.9 in 210 seconds, Group B in 610 seconds, and Group C in 654 
seconds (Alsaeed et al., 2017).  Of note, the mean values for the BMI in each Group, A, 
B, and C, was 38, 46, and 46, respectively.  Alsaeed et al. (2017) determined the time to 
reach a TOFR of 0.9 was significantly decreased in Group A versus Groups B and C (P 
<0.05), and therefore concluded that sugammadex reverses neuromuscular blockade 
induced by rocuronium more rapidly than neostigmine. 
Laparoscopic surgical procedures. Laparoscopic surgical procedures often 
require deep neuromuscular blockade until the end of an operation.  Geldner et al. (2012) 
conducted a study to compare recovery from different depths of rocuronium-induced 
neuromuscular blockade.  Sugammadex was given during deep neuromuscular blockade, 
versus neostigmine administration at the reappearance of moderate blockade in patients 
undergoing laparoscopic surgery (Geldner et al., 2012). 
Geldner et al. (2012) utilized a multicenter, quantitative, randomized, blinded, 
control trial in their research.  Ten study sites were enrolled: three in Russia; four in 
Germany; two in Finland; and one in the UK. A total of 140 participants enrolled in the 
study were randomized to receive either 4mg/kg of sugammadex to reverse deep 
neuromuscular blockade (n=70) or 50mcg/kg of neostigmine, plus atropine 10mcg/kg 
(n=70) to reverse moderate neuromuscular blockade.  The efficacy variable was the 
elapsed time from reversal agent administration to recovery of the TOF ratio to 0.9. 
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Patients who received sugammadex recovered 3.4 times faster than patients who 
received neostigmine despite the differences in depth of neuromuscular blockade; 
recovery times of 2.4 minutes and 8.4 minutes, respectively.  Times recorded from last 
dose of rocuronium to recovery were 13.3 minutes in the sugammadex group and 35.2 
minutes in the neostigmine group (Geldner et al., 2012).  Documentation of the last dose 
of rocuronium eliminated administration as being a confounding variable of causality 
between sugammadex and neostigmine time to reversal.  ANOVA bivariate statistical 
analysis was utilized to determine statistical significances between the control and 
intervention group.  Recovery times were statistically significant in supporting the time to 
reestablish neuromuscular function was decreased when sugammadex was administered 
for NMBA reversal (Geldner et al., 2012).   
Next, the theoretical framework utilized for this systematic review will be 
discussed. 
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Theoretical Framework 
Systematic reviews and meta-analyses have become increasingly prevalent in 
health care due to their ability to compile important data which influences clinical 
practice guidelines and decision-making (Moher, Liberati, Tetzlaff, Altman, & PRISMA 
Group, 2009).  Critical content analysis and quality reporting of systematic reviews has 
been imperative due to the paramount influence systematic reviews have on clinical 
practice.  To improve the quality reporting of systematic reviews, Moher et al. (2009) 
developed the Preferred Reporting Items for Systematic review and Meta-Analyses 
(PRISMA) statement, which allows the reader full transparency to assess the strengths 
and weaknesses of any systematic review.  The PRISMA statement and Critical 
Appraisal Skills Programme (CASP) critical appraisal tool will be utilized to guide this 
systematic review.  
The PRISMA statement consists of an explicit 27-item checklist (Appendix B), 
comprised of seven domains, which include: title, abstract, introduction, methods, results, 
discussion, and funding (Moher et al., 2009).  The checklist sets forth the minimum set of 
criteria required for evidence-based research studies included in a systematic review 
(Moher et al., 2009).  The PRISMA checklist ensured completeness of extracted data 
from each of the included randomized control trials.  
The PRISMA statement also included a four-phase flow diagram (Appendix C), 
which was utilized to exhibit the selection process for study inclusion and exclusion in 
this systematic review.  The product of the flow diagram provided a final number of 
eligible studies for inclusion.  Together, the PRISMA checklist and flow diagram 
provided the framework for development of this systematic review.   
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 The critical appraisal tool employed to evaluate the studies in this systematic 
review was the 11-question assessment tool from the CASP of the Centre for Evidence-
Based Medicine (Polit & Beck, 2017).  The first two questions of this appraisal tool 
screened whether the study being critically appraised possessed enough validity to 
continue reviewing (CASP, 2017).  The subsequent questions stimulated systematic 
evaluation of the research.  Additionally, each subsequent question provided prompts, 
designed to reinforce the importance of the question as it related to the research article 
(CASP, 2017).  Once the studies proved to have valid results and relevance, the CASP 
tool provided an approach to critically appraise and conclude the usefulness of the 
findings (CASP, 2017).  
The CASP tool assisted to determine the trustworthiness, results, and relevance of 
the research studies (CASP, 2017).  The CASP tool, comprised of 11 questions, was 
answered by the researcher as “yes”, “no”, or “can’t tell”.  The CASP tool examined: the 
validity of results, random assignment of participants, participant trajectory through the 
research project, “blinding” of treatments to assessors and participants, equal assortment 
and treatment, results and significance of the treatment effect, and benefit/risk ratio of the 
treatment (CASP, 2017) (Appendix E).   
Next, the method section will be presented and discussed.  
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Method 
Purpose 
The purpose of this paper was to complete a systematic review to compare the 
administration of sugammadex versus neostigmine and time to reestablish normal 
muscular function, as evidenced by a TOF ratio of 0.9.   The research question 
investigated was: Is there a difference in time to re-establish normal muscular function, as 
evidenced by a TOFR of 0.9, when sugammadex versus neostigmine is administered?  
Inclusion/Exclusion Criteria 
 Inclusion criteria consisted of randomized control trials conducted within the last 
ten years which included the following: adult surgical population (18 years of age or 
older); American Society of Anesthesiologist (ASA) Class I-IV patients; elective surgical 
procedures; use of rocuronium for neuromuscular blockade; use of TOF measurement to 
measure reversal agents; and use of sugammadex as a reversal agent and neostigmine as 
the comparative agent. 
 Exclusion criteria included: literature over ten years old; ASA class V patients; 
emergent cases; pediatric cases (less than 18 years of age); use of alternate tools to assess 
return of neuromuscular function; and use of other non-depolarizing steroidal NMBA’s.  
Search Strategy 
 The primary databases used for the literature search were PubMed, CINHAL with 
full text, and the Cochrane Library.  An initial search of the term “neuromuscular 
blockade” was conducted in each database.  The search was narrowed down further with 
the terms: “neostigmine”, “sugammadex”, and “rocuronium”.  The search was limited to 
randomized control trials from January 2007 to June 2018.  Results were filtered to 
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include articles written in English and then individually reviewed to determine if the 
criteria had been met for inclusion in this systematic review.  
Data Collection and Synthesis  
 Articles were reviewed methodically, and each individual study was transferred 
into two data collection tables created by this author.  Data collection tables were created 
and tailored to meet the focus of this systematic review.  Data collected and displayed in 
table 1 included: site/sample, method/design, time to TOFR of 0.9 with sugammadex, and 
time to TOFR of 0.9 with neostigmine.  Data collected and displayed in table 2 included: 
type of elective procedure, adverse events, results, and limitations (Appendix D). 
Table 1 – Data Collection Tool 1 
Site/Sample Method/Design 
 
Time to TOFR of 0.9 
with Sugammadex 
Time to TOFR of 0.9 
with Neostigmine 
    
 
Table 2 – Data Collection Tool 2 
Type of Elective Procedure Adverse Events Results Limitations 
    
 
Critical Appraisal Tools  
 Critical appraisal of research allows the investigator to evaluate the findings in a 
systematic way and utilize findings to make clinical practice decisions.  The CASP tool 
was utilized to critically appraise the randomized control trials to determine the 
credibility of the studies included in this systematic review.  All 11 questions regarding 
fairness, equality, and randomization of participants; measured outcomes; generalizability 
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of results; and risk-benefit analysis of trials were answered for each study to reach a 
comprehensive conclusion regarding the scientific integrity of the research (CASP, 2017) 
(Appendix E).   
Cross Analysis  
 After individual analysis, all randomized control trials were cross analyzed to 
compare data.  The cross-study analysis evaluated the similarities and differences 
between the time to return to a TOFR of 0.9 when sugammadex versus neostigmine was 
administered.  Additionally, the type of surgical procedure was compared across studies 
to determine whether the type of surgery impacted the results.  The information was 
recorded in the data collection table below (Table 3) (Appendix F). 
Table 3 – Cross Study Analysis 
Author Time to TOFR of 0.9 with 
Sugammadex 
Time to TOFR of 0.9 with 
Neostigmine 
Type of Surgical 
Procedure 
    
 
The data collection, critical appraisal and cross analysis results are reported in 
narrative format in this systematic review.  
Dissemination of Findings 
 Findings from this systematic review were disseminated through a major paper 
and poster presentation.  The optimal audience reached was student and certified 
registered nurse anesthetists, who would be able to translate these findings into clinical 
practice.  Future research, including cost-analysis statistics, would be warranted to 
determine whether sugammadex versus neostigmine for reversal of rocuronium-induced 
neuromuscular blockade is cost-effective.  
 Next, the results section will be discussed. 
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Results 
 The PRIMSA flow diagram (Appendix C), as well as the inclusion and exclusion 
criteria previously discussed, were utilized for selection of randomized control trials 
included in this systematic review.   The PRISMA flow diagram exhibited below (figure 
1.) displays the breakdown of the search strategy. 
 
Figure 1. PRISMA Flow Diagram 
The original search of the term “neuromuscular blockade” yielded 202 results.  Of 
the 202 results, articles were screened for duplicates.  Removal of duplicate research 
ceded 139 results for review.  The additional terms “neostigmine”, “sugammadex”, and 
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“rocuronium” were searched, which yielded 44 results for review.  The titles and 
abstracts were evaluated for inclusion and exclusion criteria specific to this systematic 
review.  The final five randomized control trials that met this systematic review’s 
inclusion criteria were analyzed accordingly.   Key information was extracted and 
recorded into the data collection tables in Appendix D.  Additionally, the studies were 
critically appraised using the CASP checklist (Appendix E).  The following information 
summarized the results obtained from the data collection tables.     
The randomized control trial conducted by Wu et al. (2014) (Appendix D1) 
demonstrated efficacy between sugammadex 2mg/kg vs. neostigmine 50mcg/kg in 
patients 18-64 years old of Caucasian and Chinese descent, undergoing elective surgery.  
Patients were enrolled from February 2010 to September 2010 at ten various sites; six 
sites in China and four sites in Europe.  Subjects included for enrollment were 
undergoing elective surgery with propofol anesthesia, and rocuronium for NMB.  
Additionally, subjects were ASA Class I – III and never have emigrated from their birth 
country.  A total of 289 subjects were enrolled. The authors calculated a sample size of 
115 Chinese subjects required to give a power of 95%.  Due to prior studies concluding 
efficacy in Caucasian subjects, the authors determined 30 Caucasian subjects per 
treatment group were required to give a power of 95%.  A central randomization system 
was utilized to assign treatment groups; the experimental group received sugammadex 
2mg/kg and the control group received neostigmine 50 mcg/kg + atropine 10-20mcg/kg. 
Anesthesia was induced and maintained with IV propofol for the elective surgical 
procedure.  TOF baseline monitoring was recorded prior to the administration of 
rocuronium.  Rocuronium 0.6mg/kg was administered to facilitate tracheal intubation. 
26 
 
Maintenance doses of 0.1-0.2mg/kg were administered as required throughout the 
anesthetic.  Toward the conclusion of surgery, at the reappearance of a T2 twitch, the 
experimental group received sugammadex 2mg/kg and the control group received 
neostigmine 50mcg/kg + atropine to reverse rocuronium-induced neuromuscular 
blockade.  Following administration of reversal agents, the time to recover a TOF ratio of 
0.9 was recorded.  The authors found that sugammadex 2mg/kg provided rapid reversal 
of rocuronium-induced neuromuscular blockade when compared with neostigmine in 
both Chinese and Caucasian subjects (p value of 0.0001).  Chinese subjects who received 
sugammadex recovered to a TOF ratio of 0.9 in 1.6 minutes versus 9.1 minutes in 
Chinese subjects who received neostigmine.  Caucasian subjects recovered to a TOF ratio 
of 0.9 in 1.4 minutes and 6.7 minutes after receiving sugammadex and neostigmine, 
respectively.  
The study demonstrated (Appendix D1) there was a significantly faster time to 
recover to a TOF ratio of 0.9 in both Chinese and Caucasian subjects who received 
sugammadex 2mg/kg.  Adverse events reported included: bradycardia and 
hypersensitivity reactions to the reversal agents.  Of the eleven reported cases of 
bradycardia, ten of the cases used neostigmine, while only one Chinese subject 
experienced bradycardia with sugammadex.  Hypersensitivity reactions were reported in 
ten Chinese subjects, seven received sugammadex, and three received neostigmine.  The 
authors identified that interethnic differences were likely to be multifactorial, and no 
obvious limitations were reported in the study.   
Critical analysis of the Wu et al. (2014) study using the CASP checklist 
(Appendix E1) revealed all except two of the critical appraisal questions were scored as 
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“yes”.  The first question scored as “no” regarded whether patients, health workers, and 
study personnel were ‘blind’ to treatment.  In Wu et al. (2014), patients who consented to 
study enrollment were blinded to the treatment received.  The study investigators were 
blinded to treatment, however, the anesthesia provider administering the drug was not 
blinded.  The second question scored as “no” regarded whether the groups were similar at 
the start of the trial.  Of the 289 subjects enrolled, 230 Chinese subjects were divided into 
two treatment groups, and 59 Caucasian subjects were further divided into two treatment 
groups.  Gender composition of the groups was not classified by the authors, however 
racial differences were purposefully categorized at the inception of this study.   Aside 
from these two questions, the trial clearly addressed a focused issue, randomized the 
assignment of patients to treatments, and properly accounted for all patients at the study’s 
conclusion.  All patients enrolled in the study were treated equally. 
The next randomized control trial by Woo et al. (2013) (Appendix D2) was 
conducted to evaluate the efficacy of rocuronium-induced neuromuscular blockade 
reversal in Korean patients when sugammadex versus neostigmine was administered as 
the reversal agent.  The study was a randomized, parallel-group, active-controlled, safety 
assessor-blinded phase IV study, conducted at seven sites in the Republic of Korea.  
Enrollees were of Korean descent, ASA class I-III, undergoing an elective surgical 
procedure under general anesthesia using rocuronium for NMB.  A sample size of 128 
subjects undergoing elective surgery were randomized on a 1:1 basis to receive either 
sugammadex 2mg/kg or neostigmine 50mcg/kg + glycopyrrolate 10mcg/kg.  The authors 
determined a sample size of 50 Korean subjects per treatment group would be required to 
provide a power of 95%, testing at a significance level of 0.05.  Anesthesia was induced 
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with IV propofol and maintained with inhalational sevoflurane.  Neuromuscular 
monitoring was established, subsequently rocuronium 0.6mg/kg was administered to 
facilitate endotracheal intubation.  Maintenance doses of rocuronium 0.1- 0.2mg/kg were 
administered as required throughout the anesthetic.  During the conclusion of surgery, at 
the appearance of a T2 twitch, a solitary dose of sugammadex 2mg/kg or neostigmine 
50mcg/kg + glycopyrrolate was administered to reverse neuromuscular blockade.  Time 
elapsed from administration of reversal agent to recovery of a TOF ratio of 0.9 was 
recorded.  The authors concluded mean time to recover a TOF ratio of 0.9 was 1.8 
minutes in Korean subjects who received sugammadex, and 14.8 minutes in subjects who 
received neostigmine (p < 0.0001).  Treatment related adverse events reported were of 
mild-to-moderate intensity.  Four subjects who received sugammadex had reactions that 
included: bradycardia (n=1) and headache (n=3).  Six subjects who received neostigmine 
reported headache (n=2), nausea (n=1), recurrence of NMB (n=1), rash (n=1), and 
hypotension (n=1).  The authors did not report limitations of the study. 
Critical appraisal of the Woo et al. (2013) study (Appendix E2) identified all 
subjects were randomized into one of two treatment groups to receive either sugammadex 
or neostigmine, however the specific method utilized for randomization was not disclosed 
by study investigators.  All questions except one, were scored as “yes” on the CASP tool.  
The single question that scored “no” addressed whether patients, health workers, and 
study personnel were ‘blind’ to treatment.  Patients and study investigators were blinded 
to treatment.  The anesthesiologist administering either sugammadex or neostigmine was 
not blinded, however was prohibited from revealing the assigned treatment group to 
study investigators.  Both treatment groups were similar at the start of the trial, and the 
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trial addressed a clearly focused issue.  All subjects that participated in the study were 
treated equally throughout and properly accounted for at its conclusion.   
In the study by Gaszynski et al. (2011) (Appendix D3), researchers evaluated the 
efficacy of neostigmine versus sugammadex for reversal of rocuronium-induced muscle 
relaxation.  Seventy morbidly obese patients (BMI > 40) undergoing an elective bariatric 
surgical procedure were included in this single center study performed at the Medical 
University of Lodz, Poland.  Envelopes were prepared by a study investigator and used 
for participant randomization.  The experimental group was composed of 35 subjects who 
received sugammadex 2mg/kg of CBW and the control group comprised of 35 subjects 
who received neostigmine 50 mcg/kg CBW + atropine 0.02mg/kg CBW.  Both groups 
were induced using IV propofol in 1.5-2mg/kg CBW doses and maintained with an 
inhalational desflurane, oxygen, and air mixture.  Baseline TOF monitoring was obtained, 
then neuromuscular blockade was induced with rocuronium 1mg/kg of CBW to facilitate 
tracheal intubation.  If the TOFR spontaneously recovered to 1.0 during surgery, two 
additional rocuronium doses of 0.06mg/kg CBW could be administered.  At the 
conclusion of surgery at the reappearance of a T2 twitch, either sugammadex 2mg/kg 
CBW or neostigmine 50mcg/kg + atropine 0.02mg/kg CBW were administered based on 
participant randomization.  Time elapsed from administration of reversal agent to a 
TOFR of 0.9 was recorded.  Patients who received sugammadex recovered to a TOFR of 
0.9 in a mean time of 2 minutes and 44 seconds, while patients who received neostigmine 
recovered in a mean time of 9 minutes and 37 seconds.  The authors reported, with 
significance, that recovery to a TOFR of 0.9 was 3.5 times faster in patients who received 
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sugammadex (p <0.05).  Limitations of this study were the small number of participants 
which has limited application to clinical outcomes.    
Critical appraisal of the Gaszynski et al. (2011) study (Appendix E3), showed all 
but two of the CASP questions were scored as “yes”.  The trial addressed a clearly 
focused issue between two similar groups.  Additionally, all subjects that participated in 
the study were treated equally throughout and properly accounted for at its conclusion.  
The first question scored as “no” was whether patients, health workers, and study 
personnel were ‘blind’ to treatment.  Patients and study investigators were blinded to 
treatment.  The anesthesia provider administering the reversal agent was not blinded to 
treatment.  The second question scored as “no” regarded the precision of the estimate of 
the treatment effect.  The authors failed to clearly identify the sample size required to 
provide and report a power analysis.   
Illman et al. (2011) (Appendix D4) evaluated time to achieve a TOFR of 0.9 when 
sugammadex 2mg/kg versus neostigmine 50mcg/kg was administered as the reversal 
agent for rocuronium-induced neuromuscular blockade.  Fifty subjects were enrolled at 
two University hospitals in Finland.  Subjects were 18-70 years of age, ASA Class I – IV, 
undergoing elective surgery under general anesthesia.  The authors identified twenty-
three patients were required in each treatment group to give a power of 90%, testing at a 
significance level of 0.05.  Exclusion criteria included significant renal, hepatic, or 
ventilatory dysfunction, BMI > 32.5, pregnancy, patients with muscular dystrophies, and 
patients already on medications known to interfere with neuromuscular transmission.   
General anesthesia was induced according to usual practice of the study center 
with IV propofol and an IV opioid.  Rocuronium, 0.6-1mg/kg, was administered based on 
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clinical factors, duration of surgery, and facilitation of tracheal intubation.  Anesthesia 
was maintained using an inhalation agent (either sevoflurane or desflurane) and opioids.  
Neuromuscular monitoring was initiated using TOF stimulation.  Additional rocuronium 
was administered in 5-10mg doses as clinically necessary.  At the conclusion of surgery, 
computer-generated sealed envelopes were utilized to randomly assign patients to receive 
either neostigmine 50 mcg/kg + glycopyrrolate 10 mcg/kg or sugammadex 2mg/kg.  The 
reversal agent was prepared by a study nurse and administered when the anesthesiologist 
visualized a T2 twitch on TOF stimulation.  The anesthesiologist remained blinded to the 
reversal agent administered by the study nurse.  The time elapsed between a T2 twitch 
and recovery to a TOFR of 0.9 was recorded by study investigators.  Mean time to 
achieve a TOFR of 0.9 after administration of sugammadex and neostigmine + 
glycopyrrolate was 1.7 ± 0.7 minutes and 13.3 ± 5.7 minutes, respectively.  The results 
from Illman et al. (2011) concluded time to recover a TOFR of 0.9 was significantly 
shorter when sugammadex 2mg/kg was administered (P < 0.001).   
The results of this study support the use of sugammadex as a faster and more 
reliable reversal agent than neostigmine.  However, some limitations have been identified 
in the Illman et al. (2011) study.  The use of 2 different volatile agents and 3 different 
opioids may be regarded as a limitation due to varying synergistic effects of the 
anesthetic agents.  Additionally, the percent of inspired volatile agent was not reported, 
which could influence the degree of skeletal muscle relaxation. 
Critical appraisal of this study (Appendix E4) shows all critical appraisal 
questions were scored as “yes”.  All participants were properly accounted for at the trial’s 
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conclusion.  Patients, health workers, and study personnel were blinded to the treatment.  
Both groups were treated equally, and all clinically important outcomes were considered.   
 Blobner et al. (2010) (Appendix D5) included ninety-eight patients undergoing 
elective surgery, in a randomized control trial to evaluate efficacy of sugammadex versus 
neostigmine for reversal of rocuronium-induced neuromuscular blockade.  This study 
included thirteen sites in Europe.  The authors identified that to have a power of 95% 
testing at a significance level of 0.05, a total of 46 patients would have to be enrolled in 
each group.   Patients enrolled were at least 18 years old, ASA class I-III, undergoing 
general anesthesia.  Patients were excluded if they were an expected difficult intubation, 
had known renal or hepatic dysfunction, or a known contraindication to the medications 
used during the study.  
Ninety-eight patients were randomized into two groups to receive either 
sugammadex 2mg/kg or neostigmine 50mcg/kg + glycopyrrolate 10mcg/kg.  Anesthesia 
was induced with IV propofol, maintained with inhalational sevoflurane, and opioids 
were supplemented during the anesthetic as clinically indicated.  Baseline TOF 
monitoring was obtained, subsequently rocuronium 0.6mg/kg was administered to 
facilitate tracheal intubation and abolish successive twitch responses.  Maintenance doses 
of 0.1-0.2mg/kg of rocuronium were administered during the anesthetic as clinically 
indicated.  When neuromuscular blockade was no longer required, patients were allowed 
to spontaneously recover to a T2 twitch on TOF stimulation.  At the appearance of a T2 
twitch, sugammadex 2mg/kg or neostigmine 50mcg/kg + glycopyrrolate 10mcg/kg was 
administered.  Blobner et al. (2010) concluded patients who received sugammadex 
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recovered in a significantly shorter amount of time than patients who received 
neostigmine (P <0.0001), 1.5 minutes and 18.6 minutes, respectively.  
 Critical appraisal (Appendix E5) of the Blobner et al. (2010) study revealed all 
critical appraisal questions were scored as “yes” except for one that addressed whether 
patients, health workers, and study personnel were ‘blind’ to treatment.  The participants 
were blinded to treatment, as were the study personnel.  The anesthesia provider 
administering the reversal agent was not blind to treatment.  The relative distribution of 
surgical procedures was similar, and both groups were treated equally.  All participants 
were properly accounted for at the study’s conclusion.   
Cross Analysis 
 The randomized control trials included in this systematic review were cross 
analyzed (Appendix F).  The cross analysis of these studies compared time to establish a 
TOFR of 0.9 with sugammadex, time to establish a TOFR of 0.9 with neostigmine, and 
the type of elective surgical procedure which required general anesthesia.   
 All the randomized control trials included in this systematic review evaluated the 
efficacy of sugammadex versus neostigmine for reversal of rocuronium-induced 
neuromuscular blockade.  All randomized control trials used general anesthesia as the 
primary anesthetic.  All surgeries were elective, performed on ASA class I-IV patients.  
Patients with co-morbidities that could potentially affect the outcomes of the study, such 
as renal or hepatic dysfunction were excluded.   
Although surgical procedures varied or were not specifically identified, results 
were not impacted based on the type of surgery performed.  Wu et al. (2014) did not 
specify the type of surgical procedure, however the authors identified that the surgery 
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was elective.  Woo et al. (2013) investigated patients undergoing elective operations of 
the ear, nose, and larynx (48%), gynecologic (18%), digestive system and spleen (17%).  
Gaszynski et al. (2011) evaluated patients undergoing elective bariatric surgery.  Illman 
et al. (2011) did not specify the type of elective surgical procedure.  Blobner et al. (2010) 
studied patients undergoing a variety of elective operations, including: ears, nose, and 
larynx (19%); teeth, jaws, mouth, and pharynx (16%); digestive system and spleen 
(16%); urinary system, male genital organs, and retroperitoneal space (13%); 
musculoskeletal system (12%); female genital organs (9%); endocrine system (7%); eye 
and adjacent structures (4%); and mammary gland surgery (2%).  The cross-study 
analysis results supported the hypothesis that sugammadex 2mg/kg would be a reliably 
faster acting agent to reverse moderate levels of rocuronium-induced neuromuscular 
blockade, when compared to neostigmine (Appendix F).   Mild-to-moderate adverse 
effects of both sugammadex and neostigmine were reported, however the benefits of 
quickly and reliably reversing neuromuscular blockade outweighed the associated risks. 
Next, the summary and conclusions section will be presented. 
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Summary and Conclusion 
A comprehensive understanding of the neuromuscular junction and mechanism of 
action of varying muscle relaxants has been a cornerstone of modern anesthesia practice.  
A thorough literature review was conducted to highlight the importance of using 
neuromuscular blocking agents to facilitate safe surgical procedures, as well as the 
importance of properly reversing these agents.  Wiatrowski et al. (2018) identified 
residual neuromuscular blockade occurs postoperatively in 20-60% of patients who 
received non-depolarizing NMBAs.  Detrimental consequences that could potentially 
result include: aspiration from impaired reflexes, airway obstruction, and impaired 
oxygenation and ventilation requiring re-intubation (Wiatrowski et al., 2018).   
Assessment of neuromuscular blockade intraoperatively has been a standard of 
nurse anesthesia practice (AANA, 2013).  Various clinical assessments have been utilized 
to determine adequate neuromuscular recovery; however, the gold standard of recovery 
remains a TOF ratio of 0.9 as measured by AMG.  Nagelhout (2015) identified one of the 
main limitations of using cholinesterase inhibitors for reversal was the inability to 
produce a consistent and reliable TOFR of 0.9 within 30 minutes.  Naguib (2015) cited 
advantages of sugammadex to include reversal of any level of blockade within 3 minutes 
of administration, lack of muscarinic side effects, and independence of enzyme systems 
and receptors in the body.  Review of the literature warranted the need for this systematic 
review to determine the most reliable and consistent reversal agent of moderate levels, 
evidenced by a T2 twitch, of rocuronium-induced neuromuscular blockade.   
The purpose of this systematic review was to assess the efficacy of neostigmine 
versus sugammadex for reversal of moderate levels of rocuronium-induced 
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neuromuscular blockade in adult patients undergoing an elective surgery under general 
anesthesia.  Pubmed, CINHAL with full text, and the Cochrane Library databases were 
searched to find relevant articles.  The PRISMA checklist and flow diagram was utilized 
to exhibit the selection process for study inclusion.   
 After development of inclusion and exclusion criteria, a total of five studies were 
selected as meeting criteria for inclusion in this systematic review.  Each study was 
thoroughly analyzed to allow extraction of pertinent data for summarization in data 
collection tables.  Following data extraction, the five studies were critically appraised 
utilizing the CASP checklist.  An analysis across studies, which focused on the type of 
surgical procedure, and time to obtain a TOF ratio of 0.9 in both the control and 
experimental groups was conducted.   
 All five studies included in this systematic review identified that sugammadex, 
when compared to neostigmine, more reliably and consistently reversed moderate 
rocuronium-induced neuromuscular blockade to a TOFR of 0.9. There were mild-to-
moderate sugammadex-related adverse effects reported in all five studies, however, the 
benefits of reliably reversing neuromuscular blockade outweighed the risk of adverse 
outcomes.  There were some limitations identified in this systematic review.  There was 
variation among dosing methods in the studies included.  Wu et al. (2014) utilized actual 
body weight to calculate reversal agent doses, Gaszynski et al. (2011) utilized corrected 
body weight, and the remaining studies did not clearly identify the weight used to 
determine doses.  Three of the studies were financially supported by the pharmaceutical 
company Merck Sharp & Dohme Corp, which owns and manufacturers sugammadex.  
The length of the surgical procedure, timing elapsed from the last dose of rocuronium, 
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and concurrently administered anesthetic doses was not identified across studies, which 
could be considered a limitation.  An additional limitation of this systematic review could 
be that only three databases were utilized to extract randomized control trials.   
 In summary, the five randomized control trials included in this systematic review 
supported sugammadex as reliable and consistent in producing a TOFR of 0.9, in a 
significantly shorter time, when compared to neostigmine for reversal of rocuronium-
induced neuromuscular blockade. 
 Next, the recommendations and implications for advanced nursing practice will 
be discussed.   
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Recommendations and Implications for Advanced Nursing Practice 
 Residual neuromuscular blockade is a serious and potentially life-threatening state 
that increases perioperative morbidity and mortality.  Certified Registered Nurse 
Anesthetists (CRNAs), advanced practice nurses, have become integral members of the 
anesthesia care team.  CRNAs administer more than 45 million anesthetics to patients 
each year in the United States (AANA, 2019).  Anesthesia administration is both an art 
and science, in which emerging evidence and research must be continuously incorporated 
into practice in order to achieve clinical and professional competency.  
 There have been many proposed methods for assessment and evaluation of 
adequate neuromuscular recovery.  The gold standard for adequate recovery from 
neuromuscular blockade is a TOFR of 0.9 by use of AMG.  The ideal reversal agent 
would quickly and reliably achieve a TOFR of 0.9 without adverse effects.  Traditionally, 
neuromuscular blockade has been reversed with an anticholinesterase, administered 
concurrently with an anticholinergic to reduce adverse effects.  In recent years, selective 
relaxant-binding agents have been investigated to determine efficacy and reliability in 
reversing neuromuscular blockade.   
 Systematic reviews provide current information regarding the safest and most 
effective methods of administering anesthesia.  The results of this systematic review 
demonstrate sugammadex can quickly and reliably reverse moderate levels of 
rocuronium-induced neuromuscular blockade without serious adverse consequences.  All 
five studies showed faster recovery to a TOFR of 0.9 with sugammadex when compared 
to neostigmine.  It is important to note that mortality was not increased in any cohorts 
studied.   
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 Further research on patient populations beyond the scope of this systematic 
review should be conducted to determine the safety profile of sugammadex in these 
groups.  Furthermore, a cost analysis should be conducted to determine whether 
sugammadex has a comparable cost to neostigmine administered with an anticholinergic 
agent.  An additional cost analysis should be conducted to determine whether reversal 
with sugammadex affects the amount of operating room (OR) time utilized, and therefore 
the cost of overall OR time, when compared to neostigmine.  
 CRNAs are uniquely positioned to provide safe patient care to a variety of 
patients in the perioperative period.  Administration of sugammadex has been proven to 
be a faster and more reliable agent in preventing the incidence of adverse events related 
to residual neuromuscular blockade induced by rocuronium.  Although sugammadex and 
neostigmine are both effective at reversing neuromuscular blockade, there are clinical 
situations where a faster and more reliable reversal using sugammadex would be 
preferred.  For example, in a “cannot intubate and cannot ventilate” scenario immediately 
after induction of anesthesia, or when muscle relaxation is required to the end of a 
surgical procedure.  Sugammadex may also be preferential in patients who cannot 
tolerate significant variations in heart rate, which may be observed when an 
anticholinesterase agent is utilized.  These are examples of clinical situations in which the 
CRNA may want to advocate for use of sugammadex.  CRNAs can become actively 
involved in developing appropriate treatment algorithms for use of sugammadex versus 
neostigmine + glycopyrrolate within the facilities they provide anesthesia based on 
current and emerging research.  Additionally, CRNAs can educate colleagues on the 
clinical advantages of sugammadex.  The CRNA, as an advanced practice nurse, has a 
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duty to provide the most effective and appropriate care to patients, while mitigating 
adverse effects.  Sugammadex has emerged as an appropriate and effective drug to 
mitigate adverse effects of neuromuscular blockade reversal, and the CRNA should be 
knowledgeable in the appropriate use of this medication.   
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Appendix D 
Data Extraction Tables 
Table D1 – Wu, X., Oerding, H., Liu, J., Vanacker, B., Yao, S., Dahl, V., … Woo, T. (2014). Rocuronium blockade reversal with 
sugammadex vs. neostigmine: randomized study in Chinese and Caucasian subjects.  BMC anesthesiology, 14(53).  doi:10.1186/1471-
2253-14-53 
Site/Sample Method/Design Time to TOFR of 0.9 
with Sugammadex 
Time to TOFR of 0.9 
with Neostigmine 
Multi-center study (6 
sites in China & 4 sites 
in Europe) 
 
289 Subjects enrolled 
in trial (230 Chinese 
subjects & 59 
Caucasian subjects) 
 
Subjects aged 18-64 
years 
 
Undergoing Elective 
Surgery  
 
ASA Class ≤ 3 
 
Randomized, parallel group, multicenter, safety-
assessor blinded study 
 
Screening of subjects took place ≤ 7 days prior to 
treatment administration. Eligible subjects were 
randomized via a computerized central 
randomization system in a 1:1 ratio to either 
receive: sugammadex 2mg/kg or neostigmine 
50mcg/kg with atropine 10-20mcg/kg  
 
Anesthesia induced and maintained with IV 
propofol, opioids administered according to local 
practice. Rocuronium 0.6mg/kg was administered 
prior to intubation. Rocuronium maintenance doses 
of 0.1-0.2mg/kg were administered as required for 
the anesthetic. After the last dose of rocuronium, at 
the reappearance of a second twitch (T2), the 
reversal agents were administered. 
1.6 minutes in Chinese 
subjects 
 
1.4 minutes in 
Caucasian subjects 
9.1 minutes in Chinese 
subjects 
 
6.7 minutes in 
Caucasian subjects 
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Type of 
Elective 
Procedure 
Adverse Events Results Limitations 
Not specified 11 subjects experienced 
bradycardia after study drugs: 7 
Chinese subjects (1 received 
sugammadex; 6 received 
neostigmine) & 4 Caucasian 
subjects (all 4 received 
neostigmine)  
 
10 Chinese subjects 
experienced hypersensitivity 
reactions characterized by: 
mild-to-moderate rash, pruritis, 
facial swelling, & facial 
flushing: 7 Chinese subjects 
received sugammadex; 3 
Chinese subjects received 
neostigmine 
 
Sugammadex provided more rapid 
reversal of rocuronium-induced 
neuromuscular blockade compared 
with neostigmine in both Chinese & 
Caucasian subjects 
 
Chinese subjects experienced a 
recovery time that was 5.7 times 
faster with sugammadex versus 
neostigmine (p <0.0001) 
 
Caucasian subjects experienced 
recovery from rocuronium-induced 
neuromuscular blockade 4.8 times 
faster with sugammadex versus 
neostigmine (p <0.0001) 
Doses of neuromuscular blocking 
agents were based on actual body 
weight instead of ideal body weight 
 
Length of surgical procedure not 
specified 
 
Financial support provided by 
Merck Sharp & Dohme Corp.  
 
Time elapsed from last dose of 
rocuronium not specified  
 
Type of surgical procedure not 
specified 
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Table D2 – Woo, T., Kim, K.S., Shim, Y.H., Kim, M.K., Yoon, S.M., Lim, Y,J., … Chon, J.Y. (2013). Sugammadex versus 
neostigmine reversal of moderate rocuronium-induced neuromuscular blockade in Korean patients.  Korean Journal of 
Anesthesiology, 65(6), 501-507. https://dx.doi.org/10.4097/kjae.2013.65.6.501 
Site/Sample Method/Design Time to TOFR of 
0.9 with 
Sugammadex 
Time to TOFR of 0.9 
with Neostigmine 
Multi-center 
study (7 sites in 
the Republic of 
Korea) 
 
Subjects were of 
Korean descent - 
born in Korea, 
never emigrated 
from Korea, with 
a Korean home 
address (n=118) 
 
Subjects 
undergoing 
elective surgical 
procedure 
 
ASA Class ≤ 3 
 
Randomized, parallel-group, active-controlled, safety 
assessor-blinded phase IV study 
 
Subjects were randomized on 1:1 basis to receive either: 
sugammadex 2mg/kg or neostigmine 50mcg/kg plus 
glycopyrrolate 10mcg/kg for NMB reversal 
 
Anesthesia induced with IV propofol & maintained with 
sevoflurane. Opioids were administered per local practice. 
Rocuronium 0.6mg/kg was administered for intubation and 
was re-dosed as clinically indicated in 0.1-0.2mg/kg doses. 
After the final dose of rocuronium, at the reappearance of a 
T2, the reversal agents were administered. 
 
The anesthesia provider administering the anesthesia during 
the surgery was not blinded to the randomized study drug, 
but was not allowed to reveal the assigned treatment group 
to the safety assessor  
 
Blinded safety assessor performed safety assessments in the 
postoperative period 
1.8 minutes 
following 
administration of 
sugammadex 
2mg/kg 
14.8 minutes 
following 
administration of 
neostigmine 
50mcg/kg 
50 
 
 
 
Type of Elective Procedure Adverse Events Results Limitations 
Operations of the ear, nose, 
& larynx (48%) 
 
Operations of female genital 
organs (18%) 
 
Operations of digestive 
system & spleen (17%) 
Treatment related adverse 
events: 
 
- 4 subjects in 
sugammadex group 
(bradycardia, n=1; 
headache, n=3) 
 
- 6 subjects in 
neostigmine group 
(headache, n=2; 
nausea, n=1; recurrence 
NMB, n=1; rash, n=1; 
hypotension, n=1) 
 
Recovery from rocuronium-
induced neuromuscular 
blockade was 8.1 times faster 
with sugammadex versus 
neostigmine in Korean subjects 
(P<0.0001) 
Doses of study related drugs 
was not specific regarding 
whether ideal body weight or 
actual body weight was used 
to determine dosing 
 
Time elapsed from last dose 
of rocuronium not specified 
 
Length of surgical procedure 
not specified 
 
 Financial support provided 
by Merck Sharp & Dohme 
Corp. 
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Table D3 – Gaszynski, T., Szewczyk, T., & Gaszynski, W. (2011). Randomized comparison of sugammadex and neostigmine for 
reversal of rocuronium-induced muscle relaxation in morbidly obese undergoing general anaesthesia. British Journal of Anaesthesia, 
108(2), 236-239.  doi: 10.1093/bja/aer330 
Site/Sample Method/Design Time to TOFR 
of 0.9 with 
Sugammadex 
Time to TOFR 
of 0.9 with 
Neostigmine 
Single center 
study performed 
at the Medical 
University of 
Lodz, Poland 
 
70 morbidly 
obese subjects 
(BMI > 40) 
requiring general 
anesthesia & 
muscle relaxation 
with rocuronium  
 
Undergoing 
elective bariatric 
surgery  
Prospective, randomized, safety-assessor blinded study 
 
Subjects were randomized to receive either: sugammadex 2mg/kg of 
corrected body weight (CBW) or neostigmine 0.05mg/kg CBW with 
atropine 0.02mg/kg CBW. Envelopes previously prepared by the 
investigator were used for randomization. 
 
Both groups had anesthesia induced with propofol 1.5-2 mg/kg CBW. 
Fentanyl 0.05 mg/kg CBW administered for analgesia.  Anesthesia was 
maintained with an air, oxygen, & desflurane mixture.  Volume % of 
desflurane was based on age, clinical status, & monitoring. Neuromuscular 
blockade was induced using rocuronium 1 mg/kg CBW.  A maximum of 
two additional doses of rocuronium 0.06mg/kg CBW were given when a 
TOFR reached 1. 
 
At surgery completion and reappearance of T2 twitch, reversal agents were 
administered, and time recorded.  
 
A blinded investigator continued to monitor TOF stimulation & perform 
safety assessments in the postoperative period  
2 minutes 44 
seconds 
following 
administration 
of sugammadex 
2mg/kg CBW 
9 minutes 37 
seconds 
following 
administration of 
neostigmine 
0.05mg/kg CBW 
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Type of Elective 
Procedure 
Adverse Events Results Limitations 
Elective bariatric 
surgery 
Treatment related 
adverse events 
included: 
 
2 subjects in 
sugammadex group 
reported “a strange taste 
in the mouth” 
 
3 subjects in the 
negostigmine group had 
significant bradycardia 
that required additional 
administration of 
atropine 
Total dose of 
rocuronium was 
comparable between 
the two groups 
(sugammadex 
group: 87.9mg; 
neostigmine group: 
85.6mg). 
 
Mean time to 
achieve TOFR 0.9 
was 3.5 times 
shorter in the 
subjects who 
received 
sugammadex 
(P<0.05) 
Investigator previously prepared envelopes for randomization, 
which may increase risk for selection bias 
 
Small sample size 
 
ASA classification & age of participants omitted from reported 
data 
 
Use of CBW may have resulted in under-dosing in the obese 
patient. Use of CBW was utilized based on recommendations 
from prior authors. Manufacturer recommends dosing on actual 
body weight.  
 
Standard anesthesia practice in Poland utilizes paired use of 
atropine & neostigmine; glycopyrrolate may be better paired with 
neostigmine & may have altered the prevalence of adverse events 
reported 
 
Percent of inspired volatile agent not reported, higher doses may 
potentiate neuromuscular blockade 
 
Length of surgical procedure not specified 
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Table D4 – Illman, H.L., Laurila, P., Antila, H., Meretoja, O., Alahuhta, S., & Olkkola, K. T. (2011).  The duration of residual 
neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train-of-four monitoring.  
Anesthesia & Analgesia, 112(1), 63-68. doi: 10.1213/ANE.0b013e3181fdf889 
Site/Sample Method/Design Time to TOFR 
of 0.9 with 
Sugammadex 
Time to TOFR 
of 0.9 with 
Neostigmine 
Multi-sites at 
two University 
Hospitals 
(Oulu; Turku) 
in Finland 
 
50 subjects 
enrolled  
 
Subjects male 
& female 
 
Subjects aged 
18-70 years 
 
Subjects BMI ≤ 
32.5 
 
Undergoing 
elective surgery 
 
ASA Class ≤ 4 
Double-blind, randomized, multi-center study 
 
Subject randomization into 2 groups at end of surgery, accomplished via computer-
generated sealed envelopes with written instructions to prepare either: neostigmine 
50 mcg/kg + glycopyrrolate 10 mcg/kg or sugammadex 2mg/kg for NMB reversal.  
 
Previous studies utilized to calculate 23 subjects would be required in each group to 
gain a level of significance of P=0.05 and power of 90%. 
 
Anesthesia induced with propofol + opioid. Depending on clinical factors & 
expected duration of surgery, rocuronium 0.6-1mg/kg (actual body weight) 
administered.  Anesthesia maintained with sevoflurane or desflurane and opioids. 
Additional 5-10mg rocuronium administered when 2 twitch responses appeared 
visually. 
 
Degree of NMB measured with 1 monitor (acceleromyography) but two different 
methods: objective monitoring & visual evaluation by the anesthesiologist.  The 
provider was blinded to the objective/quantified measurements. 
 
At end of surgery, the assisting investigator administered the reversal drug when the 
anesthesia provider had detected 2 visual twitch responses. Time recorded by the 
1.7 ± 0.7 
minutes 
following 
administration 
of 
sugammadex 
2mg/kg 
13.3 ± 5.7 
minutes 
following 
administration 
of neostigmine 
50mcg/kg + 
glycopyrrolate 
10mcg/kg 
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anesthesia provider when 3 and 4 twitches and no visual fade was detected after 
administration of reversal. Provider remained blinded to reversal drug administered. 
 
 
Type of 
Elective 
Procedure 
Adverse Events Results Limitations 
Not specified 1 subject experience 
postoperative nausea 
after receiving 
neostigmine 
 
No other adverse events 
were reported from either 
group.  
All enrolled subjects completed the study, however 2 
subjects excluded for technical failure of the 
acceleromyometry device (n=1 neostigmine; n=1 
sugammadex) and 1 subject excluded (n=1 
neostigmine) for waking up from anesthesia before 
TOFR 0.9 established.   
 
Final analysis included: Neostigmine (n= 23) & 
sugammadex (n=24)  
 
Sugammadex was clinically & statistically faster in 
reversing neuromuscular blockade from rocuronium (P 
< 0.001) 
 
Type of surgical procedure not 
specified 
 
2 different volatile agents & 3 
different opioids were utilized 
 
Length of surgical procedure 
not specified. 
 
Not specified whether doses of 
reversal agents were based on 
actual vs. ideal body weight  
 
Percent of inspired volatile 
agents not reported, higher 
doses may potentiate 
neuromuscular blockade 
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Table D5 – Blobner, M., Eriksson, L.I., Scholz, J., Motsch, J., Rocca, G.D., & Prins, M.E. (2010). Reversal of rocuronium-induced 
neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: Results of a randomized 
controlled trial.  European Journal of Anaesthesiology, 27(10). doi: 10.1097/EJA.0b013e32833d56b7 
Site/Sample Method/Design Time to TOFR 
of 0.9 with 
Sugammadex 
Time to TOFR of 
0.9 with 
Neostigmine 
European, 13 
center study 
 
Age ≥ 18 
years 
 
No 
restrictions 
on subject 
body weight 
 
Male & 
female 
subjects 
included 
 
Undergoing 
elective 
surgery under 
general 
anesthesia  
 
Multi-center, randomized, parallel-group, comparative, active-controlled, 
safety-assessor-blinded trial. Researched determined to have a power of 95% 
to detect a difference, a minimum of 46 subjects needed to be enrolled in 
each group. N=49 for each group was utilized in case subjects dropped out of 
the study. Patients were randomized to receive rocuronium or vecuronium; 
only the results of the subjects who received rocuronium are published in this 
study.  Subjects who received rocuronium were randomized to receive either: 
sugammadex 2mg/kg or neostigmine 50mcg/kg + glycopyrrolate 10mcg/kg. 
 
Anesthesia induced with propofol and maintained with sevoflurane + opioid 
supplementation as clinically indicated. After baseline acceleromyography 
recording, rocuronium 0.6mg/kg administered for intubation.  Maintenance 
doses of 0.1-0.2mg/kg administered based on clinical need.  
 
When NMB was no longer required, subjects were allowed to recover to a 
reappearance of T2 twitch, then reversal agents were administered IV. 
Sevoflurane concentrations were maintained for a period of 10 minutes 
following reversal agent administration or decreased when a TOFR 0.9 was 
achieved. Any patient who did not return to a TOFR of 0.9 within 10 minutes 
of reversal agent administration remained sedated, intubated, & ventilated in 
the recovery room until a TOFR 0.9 was achieved for safe extubation.  
 
1.5 minutes to 
recover to a 
TOFR 0.9 
following 
administration of 
sugammadex 
2mg/kg 
18.6 minutes to 
recover to a TOFR 
0.9 following 
administration of 
neostigmine 
50mcg/kg + 
glycopyrrolate 
10mcg/kg 
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ASA Class ≤ 
3 
Postoperative clinical assessments were performed by the blinded safety 
assessor.  
 
 
Type of Elective Procedure Adverse Events Results Limitations 
Distribution of surgical procedures: 
 
Operations of ear, nose, & larynx (19%) 
 
Operations of teeth, jaws, mouth, & 
pharynx (16%) 
 
Operations of digestive system & spleen 
(16%) 
 
Operations of urinary system, male genital 
organs, & retroperitoneal space (13%) 
 
Operations of musculoskeletal system 
(12%) 
 
Operations of female genital organs (9%) 
 
Operations of endocrine system (7%) 
 
Operations of eye & adjacent structure 
(4%) 
 
Operations of mammary gland surgery 
(2%) 
Drug related adverse events 
occurring in 1+ subjects in 
either group: 
 
o Dry mouth (neostigmine = 
3; sugammadex =3) 
o Nausea (neostigmine =2; 
sugammadex =2) 
o Procedural HTN 
(sugammadex = 2) 
o Vomiting (sugammadex 
=2) 
o Albumin in urine 
(neostigmine =2) 
 
Isolated adverse events: 
o Severe abdominal pain 
(sugammadex = 1) 
o Severe bradycardia 
(neostigmine = 1) 
 
Serious Adverse Events (not 
specified): 
o Sugammadex =2 
o Neostigmine = 3 
Treatment groups were 
comparable regarding: age, 
weight, & height 
 
Distribution of surgical 
procedures was comparable 
across treatment groups 
 
Maintenance doses of inspired 
sevoflurance and total doses of 
rocuronium were comparable 
between groups 
 
All study sites had consistent 
results when comparing 
sugammadex vs. neostigmine 
 
Sugammadex was faster in 
attaining a TOFR 0.9 than 
neostigmine when rocuronium-
induced NMB was present  
(P < 0.0001) 
  
Financial support 
provided by Merck 
Sharp & Dohme 
Corp. 
 
Doses of study 
related drugs was 
not specific 
regarding whether 
ideal body weight 
or actual body 
weight was used to 
determine dosing 
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Appendix E 
Critical Appraisal Skills Programme (CASP) Tables 
 11 Questions Yes Can’t 
Tell 
No 
1 Did the trial address a clearly focused issue? 
 
   
2 Was the assignment of patients to treatments 
randomized? 
 
   
3 Were all the patients who entered the trial properly 
accounted for at its conclusion? 
   
4 Were patients, health workers, and study personnel 
‘blind’ to treatment? 
   
5 Were the groups similar at the start of the trial? 
 
   
6 Aside from the experimental interventions, were the 
groups treated equally? 
   
7 How large was the treatment effect? 
 
   
8 How precise was the estimate of the treatment effect? 
 
   
9 Can the results be applied in your context? (Or to the 
local population?) 
   
10 Were all clinically important outcomes considered? 
 
   
11 Are the benefits worth the harms and costs? 
 
   
 
(CASP, 2017) 
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Table E1 - Wu, X., Oerding, H., Liu, J., Vanacker, B., Yao, S., Dahl, V., … Woo, T. 
(2014). Rocuronium blockade reversal with sugammadex vs. neostigmine: randomized 
study in Chinese and Caucasian subjects.  BMC anesthesiology, 14(53).  
doi:10.1186/1471-2253-14-53 
 11 Questions Yes Can’t 
Tell 
No 
1 Did the trial address a clearly focused issue? Yes, the 
primary objective of this study was to evaluate the efficacy and 
safety of sugammadex versus neostigmine to reverse 
rocuronium-induced neuromuscular blockade in Chinese 
subjects (n=230). Caucasian subjects were included with a 
smaller sample size (n=59) since efficacy had been previously 
established in Caucasian subjects in previous studies.  A 
sample of ASA I, II, III adults undergoing elective surgery with 
general anesthesia were recruited.  
ü   
2 Was the assignment of patients to treatments randomized?  
Yes, subjects were randomized via a central, computer-
generated randomization schedule.  Subjects were randomized 
in a 1:1 ratio to received either sugammadex 2mg/kg or 
neostigmine 50mcg/kg with atropine 10-20mcg/kg. 
 
ü   
3 Were all the patients who entered the trial properly 
accounted for at its conclusion?  Yes, 308 subjects were 
included for randomization of treatment. 17 discontinued prior 
to treatment.  Of the 291 subjects who received treatment, 2 
were excluded from data analysis. 
ü   
4 Were patients, health workers, and study personnel ‘blind’ 
to treatment?  Patients who consented to study participation, 
were blinded to whether they received sugammadex or 
neostigmine + atropine.  Anesthesia providers administering 
the medications were not blinded to the treatment in which 
their patient received.  Study personnel in the postoperative 
period were blinded to treatment.   
  ü 
5 Were the groups similar at the start of the trial?  The 
groups were racially divided at the start of the study, as the 
purpose of this trial was to determine efficacy in Chinese 
subjects. (Since efficacy had already been established in 
Caucasian subjects in previous studies.) Characteristics that 
were similar across groups included: elective surgical 
procedure, ASA class I, II, III, and rocuronium-induced 
  ü 
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neuromuscular blockade with propofol anesthesia.  Gender 
differences were not revealed. 
6 Aside from the experimental interventions, were the groups 
treated equally? Yes. Anesthesia induction and maintenance 
was determined by the subject’s clinical needs.  Monitoring 
devices utilized were standardized across groups.  There were 
no gross differences noted in equality between groups. 
ü   
7 How large was the treatment effect?  A significantly faster 
recovery to a TOFR of 0.9 was assessed in both Chinese and 
Caucasian treatment groups that were given sugammadex when 
compared to neostigmine.  The authors estimated the time to 
achieve of TOFR of 0.9 in Chinese subjects was 5.7 times 
faster with sugammadex versus neostigmine (P < 0.0001).  In 
Caucasian subjects, the authors estimated recovery to a TOFR 
of 0.9, 4.8 times faster with sugammadex versus neostigmine 
(P < 0.0001) 
ü   
8 How precise was the estimate of the treatment effect?  The 
authors determined that 115 Chinese subjects and 30 Caucasian 
subjects per treatment group would have to be enrolled to give 
a power of 95% and a significance level of 0.05. 
ü   
9 Can the results be applied in your context? (Or to the local 
population?)  The patient population fits this systematic 
review’s inclusion criteria.  The results of this study directly 
apply to the context of this systematic review.  
ü   
10 Were all clinically important outcomes considered?  The 
outcomes to be assessed in this systematic review were present 
in this study.   
ü   
11 Are the benefits worth the harms and costs?  The most 
severe adverse events assessed in the study included 
bradycardia and hypersensitivity reactions, which are potential 
risks of any medication administered under general anesthesia.  
The benefits of receiving the study drug outweighed the risks. 
ü   
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Table E2 - Woo, T., Kim, K.S., Shim, Y.H., Kim, M.K., Yoon, S.M., Lim, Y,J., … Chon, 
J.Y. (2013). Sugammadex versus neostigmine reversal of moderate rocuronium-induced 
neuromuscular blockade in Korean patients.  Korean Journal of Anesthesiology, 65(6), 
501-507. https://dx.doi.org/10.4097/kjae.2013.65.6.501 
 11 Questions Yes Can’t 
Tell 
No 
1 Did the trial address a clearly focused issue? The purpose 
of this study was to establish the safety and efficacy of 
sugammadex versus neostigmine as the reversal agent for 
rocuronium-induced neuromuscular blockade in Korean 
patients.  A sample of patients ASA class I, II, III, undergoing 
an elective surgical procedure under general anesthesia using 
rocuronium for induction and maintenance of neuromuscular 
blockade were included.  Subjects were of Korean descent, 
born in Korea, with a current Korean home address, and never 
having emigrated out of Korea.   
ü   
2 Was the assignment of patients to treatments 
randomized?  Patient were randomized into 2 groups on a 
1:1 basis, however the study personnel did not provide 
specific information on how the randomization process was 
completed. 
 
ü   
3 Were all the patients who entered the trial properly 
accounted for at its conclusion?  A total of 128 patients 
were randomized into the study.  A patient disposition chart 
was included to diagram the flow of subjects throughout the 
study.  64 patients were allocated into each study group. 4 
subjects from each group did not receive the intervention for 
“administrative reasons”. 1 subject from each group was 
excluded from analysis due to lacking efficacy data.  Of the 
final 59 subjects in each group, 2 subjects in the neostigmine 
group were excluded due to “major protocol violations”.   
ü   
4 Were patients, health workers, and study personnel 
‘blind’ to treatment?  Patients were blinded to the treatment 
they received.  The anesthesiologist administering the 
randomized study drug was not blinded but was prohibited 
from revealing the assigned treatment group to the safety 
assessor postoperatively.  Study personnel in the post-
operative period were blinded to the treatment subjects 
received.   
  ü 
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5 Were the groups similar at the start of the trial?  Korean 
subjects ASA Class I, II, III, of adult age undergoing an 
elective surgical procedure under general anesthesia were 
included in both groups. No significant differences between 
the two groups regarding patient characteristics (sex, weight, 
height, race) were noted. The intention-to-treat population 
was 59 in both groups. Classification of surgical procedure 
was comparable between groups. 
ü   
6 Aside from the experimental interventions, were the 
groups treated equally? Anesthesia was induced with IV 
propofol and maintained with inhalational sevoflurane, and 
opioids were administered as clinically required in both 
groups.  Monitoring devices and rocuronium dosing was 
standardized across both groups. Both groups received the 
study drug at the reappearance of a T2 twitch on TOF 
monitoring. 
ü   
7 How large was the treatment effect?  Recovery to a TOFR 
of 0.9 was significantly faster following administration of 
sugammadex (mean time: 1.8 minutes) versus neostigmine 
(mean time: 14.8 minutes). (P < 0.0001) Statistical analysis 
revealed sugammadex to be 8.1 times faster than neostigmine. 
ü   
8 How precise was the estimate of the treatment effect? 
Study personnel calculated a sample size of 50 subjects per 
treatment group was necessary to provide a power of 95% and 
a significance level of 0.05. 
ü   
9 Can the results be applied in your context? (Or to the 
local population?)  The patient population fits this systematic 
review’s inclusion criteria.  The results of this study directly 
apply to the context of this systematic review. 
ü   
10 Were all clinically important outcomes considered? The 
outcomes to be assessed in this systematic review were 
present in this study.   
ü   
11 Are the benefits worth the harms and costs? Adverse 
events were similar between treatment groups, including 
incidences of nausea and vomiting, bradycardia, and 
headache.  These adverse events are potential risks of any 
medication administered under general anesthesia.  The 
benefits of this study outweigh the risks. 
ü   
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Table E3 - Gaszynski, T., Szewczyk, T., & Gaszynski, W. (2011). Randomized 
comparison of sugammadex and neostigmine for reversal of rocuronium-induced muscle 
relaxation in morbidly obese undergoing general anaesthesia. British Journal of 
Anaesthesia, 108(2), 236-239.  doi: 10.1093/bja/aer330 
 11 Questions Yes Can’t 
Tell 
No 
1 Did the trial address a clearly focused issue? The study 
specifically focused on the efficacy of sugammadex versus 
neostigmine for reversal of rocuronium-induced 
neuromuscular blockade in morbidly obese patients 
undergoing elective bariatric surgery.   
ü   
2 Was the assignment of patients to treatments 
randomized?  Subjects were randomized into two groups by 
a process of using previously prepared envelopes.   
ü   
3 Were all the patients who entered the trial properly 
accounted for at its conclusion?  70 trial participants were 
randomized into two groups.  35 subjects were allocated into 
each group to receive either neostigmine or sugammadex.  
Data from all 70 participants was analyzed at the conclusion 
of this study.  
ü   
4 Were patients, health workers, and study personnel 
‘blind’ to treatment?  Patients who consented to study 
enrollment, were blinded to whether they received 
sugammadex or neostigmine for reversal of rocuronium-
induced neuromuscular blockade.  The anesthesia provider 
administering the anesthetic was not blinded to treatment.  
The postoperative study investigator was blinded to the 
treatment received.  
  ü 
5 Were the groups similar at the start of the trial?  Both 
groups were electively proceeding with weight loss surgery 
under general anesthesia.  Physical characteristics of age, 
weight, height, BMI, and total rocuronium administered was 
similar between groups.  ASA classification was not reported 
(Given the surgery is elective, ASA classifications I, II, III, 
IV would be included). Both groups had an equal sample size 
of 35 participants. 
ü   
6 Aside from the experimental interventions, were the 
groups treated equally? Anesthesia was induced and 
maintained similarly, and standard monitoring was consistent 
between groups.  At the appearance of a T2 twitch, study 
medications were administered according to the 
ü   
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randomization process and the time to achieve a TOFR of 0.9 
was measured. 
7 How large was the treatment effect?  Time to TOFR of 0.9 
for patients who received sugammadex was 2 minutes 44 
seconds (mean time=2.7 minutes).  Time to TOFR of 0.9 for 
patients who received neostigmine was 9 minutes (mean time 
= 9.6 minutes).  Mean time to achieve a TOFR of 0.9 was 3.5 
times shorter in the sugammadex group (P <0.05).  Of note, 
the TOFR was 0.9 by the time the patient arrived in the 
PACU for every case that received sugammadex.  
ü   
8 How precise was the estimate of the treatment effect?  
Statistical analysis was performed using a Microsoft Excel 
workbook.  The authors did not clearly identify the sample 
size needed to provide a power analysis.  Additionally, the 
authors do not report a power analysis.  A significance level 
of 0.05 was calculated.    
  ü 
9 Can the results be applied in your context? (Or to the 
local population?)  Yes, the results of this study can be 
applied to the context of this systematic review.  The patient 
population fits this systematic review’s inclusion criteria.   
ü   
10 Were all clinically important outcomes considered? The 
outcomes to be assessed in this systematic review were 
present in this study.   
ü   
11 Are the benefits worth the harms and costs? Two patients 
who received sugammadex reported a strange taste in their 
mouths, no other side effects from sugammadex were 
reported.  Three patients who received neostigmine were 
observed to be bradycardic.  No further side effects from 
neostigmine were reported.  The benefits of this study 
outweigh the risks.  
ü   
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Table E4 - Illman, H.L., Laurila, P., Antila, H., Meretoja, O., Alahuhta, S., & Olkkola, K. 
T. (2011).  The duration of residual neuromuscular block after administration of 
neostigmine or sugammadex at two visible twitches during train-of-four monitoring.  
Anesthesia & Analgesia, 112(1), 63-68. doi: 10.1213/ANE.0b013e3181fdf889 
 11 Questions Yes Can’t 
Tell 
No 
1 Did the trial address a clearly focused issue? Yes, the main 
objective of this study was to determine the time gap between 
the T2 twitch to the return of a TOFR of 0.9 when either 
neostigmine or sugammadex was administered for reversal of 
rocuronium-induced neuromuscular blockade.  
ü   
2 Was the assignment of patients to treatments randomized?  
Anesthetized patients were randomized to receive either 
sugammadex or neostigmine at the conclusion of their surgical 
procedure.  Randomization was achieved by using computer-
generated sealed envelopes.  The envelope contained written 
instructions to prepare either neostigmine or sugammadex.   
 
ü   
3 Were all the patients who entered the trial properly 
accounted for at its conclusion?  All 50 patients who 
enrolled in the study were accounted for at conclusion.  25 
patients were allocated into each group to receive either 
neostigmine or sugammadex. Data from 2 patients who 
received neostigmine and 1 patient who received sugammadex 
was excluded for technical failure of equipment and 
awakening from anesthesia before a TOFR of 0.9 was 
established.  Therefore, data from 47 patients was resulted. 
ü   
4 Were patients, health workers, and study personnel ‘blind’ 
to treatment?  Patients who consented to study enrollment 
were blinded to which treatment they received.  The anesthesia 
provider was blinded to treatment, as the study drug was 
prepared and administered by the study nurse.  The study 
investigators were blinded to treatment. 
ü   
5 Were the groups similar at the start of the trial?  Both 
groups were comprised of men and women aged 18-70 years 
undergoing elective surgical procedures with ASA 
classifications I, II, III, IV. No significant differences between 
the groups based on gender, age, body mass index, or ASA 
classification was detected. 
ü   
6 Aside from the experimental interventions, were the 
groups treated equally?  All patients received general 
anesthesia.  Anesthesia induction and maintenance was 
ü   
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maintained with a volatile agent and opioids.  Standard 
monitoring devices were utilized.  Both groups received the 
study drug at the reappearance of a T2 twitch on TOF 
monitoring. 
7 How large was the treatment effect?  Patients who received 
sugammadex recovered to a TOFR of 0.9 significantly faster 
than patients who received neostigmine.  Return to a TOFR of 
0.9 in neostigmine group: 10.3 ± 5.5 minutes.  Return to a 
TOFR of 0.9 in sugammadex group: 0.3 ± 0.3 minutes.  
(P<0.0001) 
ü   
8 How precise was the estimate of the treatment effect?  The 
authors calculated a sample size of 23 patients in each group 
would be required to demonstrate a significance level of 0.05 
and power of 90%. A total of 50 patients were enrolled. 23 
patients received neostigmine and 24 patients received 
sugammadex. The authors determined there was a statistical 
significance in patients who received sugammadex versus 
neostigmine (P <0.0001)  
ü   
9 Can the results be applied in your context? (Or to the local 
population?)  Yes, the results of this study can be applied to 
the context of this systematic review.  The patient population 
fits this systematic review’s inclusion criteria.   
ü   
10 Were all clinically important outcomes considered? A 
TOFR of 0.9 was calculated for all patients enrolled in this 
study.  The outcomes to be assessed in this systematic review 
were present in this study.   
ü   
11 Are the benefits worth the harms and costs? One patient 
who received neostigmine reported postoperative nausea.  No 
other adverse events were reported.  The benefits outweigh the 
harms and costs. 
ü   
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Table E5 - Blobner, M., Eriksson, L.I., Scholz, J., Motsch, J., Rocca, G.D., & Prins, M.E. 
(2010). Reversal of rocuronium-induced neuromuscular blockade with sugammadex 
compared with neostigmine during sevoflurane anaesthesia: Results of a randomized 
controlled trial.  European Journal of Anaesthesiology, 27(10). doi: 
10.1097/EJA.0b013e32833d56b7 
 11 Questions Yes Can’t 
Tell 
No 
1 Did the trial address a clearly focused issue? Yes, this 
study evaluated whether reversal of rocuronium-induced 
neuromuscular blockade using sugammadex is faster than 
reversal using neostigmine.   
ü   
2 Was the assignment of patients to treatments 
randomized?  Randomization was achieved by assigning 
codes via a central-randomization system.  Patients were 
given a number in order by which they enrolled in the study, 
and a treatment code was assigned using the randomization 
system.  
ü   
3 Were all the patients who entered the trial properly 
accounted for at its conclusion?  All 98 patients who 
enrolled in the study were accounted for at conclusion.  49 
patients were allocated into each group to receive either 
neostigmine or sugammadex. Data from 1 patient in each 
group was excluded as the patient’s did not receive the study 
drug.   
ü   
4 Were patients, health workers, and study personnel 
‘blind’ to treatment?  Patients were blinded to treatment.  
The anesthetist was not blinded to the drug administered.  
Postoperatively, study personnel were blinded to treatment.  
  ü 
5 Were the groups similar at the start of the trial?  All 
patients were scheduled for an elective surgical procedure, at 
least 18 years of age and ASA class I-III.  Treatment groups 
were mostly comparable in terms of their baseline 
characteristics (age, weight, and height).  The relative 
distribution of surgical procedures was similar across the 
two groups.   
ü   
6 Aside from the experimental interventions, were the 
groups treated equally? All patients received general 
anesthesia.  Anesthesia induction and maintenance was 
comparable between the two groups.  Standard monitoring 
devices were utilized.  Both groups received the study drug 
at the reappearance of a T2 twitch on TOF monitoring. 
ü   
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7 How large was the treatment effect?  Patients who 
received sugammadex recovered to a TOFR of 0.9 in a 
geometric mean time of 1.5 minutes.  Patients who received 
neostigmine recovered to a TOFR of 0.9 in a geometric 
mean time of 18.6 minutes.  Within 5 minutes of receiving 
reversal agents, 98% of sugammadex patients, and 11% of 
neostigmine patients, recovered to a TOFR of 0.9.  The 
authors calculated a statistically significant difference in 
patients who received sugammadex versus neostigmine 
(P<0.0001) 
ü   
8 How precise was the estimate of the treatment effect?  It 
was determined by the authors a sample size of 46 patients 
in each group would be necessary to demonstrate a power of 
95% and significance level of 0.05. 
ü   
9 Can the results be applied in your context? (Or to the 
local population?)  The patient population fits this 
systematic review’s inclusion criteria.  The results of this 
study directly apply to the context of this systematic review. 
ü   
10 Were all clinically important outcomes considered? Time 
to recovery of a TOFR of 0.9 was a clinically important 
outcome assessed in this study.  Therefore, the outcomes to 
be assessed in this systematic review were present in this 
study.   
ü   
11 Are the benefits worth the harms and costs? At least one 
adverse event was reported in 84 of the study participants.  
Adverse events included: dry mouth, nausea, procedural 
hypotension, and vomiting.  Adverse events are potential 
risks of any medication administered under general 
anesthesia.  The benefits outweigh the harms and costs.  
ü   
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Appendix F 
Cross Study Analysis 
Author Time to TOFR of 
0.9 with 
Sugammadex 
 
Time to TOFR of 
0.9 with 
Neostigmine 
Type of Surgical 
Procedure 
Wu et al., 2014 1.6 minutes in 
Chinese subjects 
 
1.4 minutes in 
Caucasian subjects 
 
9.1 minutes in 
Chinese subjects 
 
6.7 minutes in 
Caucasian subjects 
Not Specified 
Woo et al., 2013 1.8 minutes  14.8 minutes  Operations of the ear, 
nose, & larynx (48%) 
 
Operations of female 
genital organs (18%) 
 
Operations of digestive 
system & spleen (17%) 
 
Gaszynski et al., 
2011 
2 minutes 44 
seconds  
9 minutes 
 
Elective bariatric surgery 
Illman et al., 2011 1.7 ± 0.7 minutes  13.3 ± 5.7 minutes  
 
Not Specified 
Blobner et al., 2010 1.5 minutes  18.6 minutes  Operations of ear, nose, & 
larynx (19%) 
 
Operations of teeth, jaws, 
mouth, & pharynx (16%) 
 
Operations of digestive 
system & spleen (16%) 
 
Operations of urinary 
system, male genital 
organs, & retroperitoneal 
space (13%) 
 
Operations of 
musculoskeletal system 
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(12%) 
 
Operations of female 
genital organs (9%) 
 
Operations of endocrine 
system (7%) 
 
Operations of eye & 
adjacent structure (4%) 
 
Operations of mammary 
gland surgery (2%) 
 
